罗欣药业(002793) - 2025 Q1 - 季度财报

Financial Performance - The company's revenue for Q1 2025 was ¥482,726,551.82, a decrease of 29.91% compared to ¥688,728,623.11 in the same period last year[4] - Net profit attributable to shareholders was ¥5,651,149.50, representing a significant increase of 115.41% from a loss of ¥36,661,627.21 in the previous year[4] - Basic earnings per share improved to ¥0.01 from a loss of ¥0.03, marking a 133.33% increase[4] - The net profit for the current period is CNY 13,830,980.74, compared to a net loss of CNY 49,632,892.41 in the previous period, indicating a significant recovery[18] - Operating profit for the current period is CNY 15,791,369.00, a turnaround from an operating loss of CNY 45,174,767.84 in the previous period[18] - The total comprehensive income for the current period is CNY 2,093,106.86, compared to a total comprehensive loss of CNY 48,314,377.49 in the previous period[19] - Basic earnings per share for the current period is CNY 0.01, recovering from a loss of CNY 0.03 per share in the previous period[19] Cash Flow and Liquidity - The net cash flow from operating activities was ¥156,575,128.68, an increase of 262.96% compared to a negative cash flow of ¥96,079,755.91 in the same period last year[4] - Cash flow from operating activities shows a net inflow of CNY 156,575,128.68, a significant improvement from a net outflow of CNY 96,079,755.91 in the previous period[21] - The company's cash and cash equivalents decreased to ¥410,737,025.84 from ¥456,677,239.94, indicating a decline of about 10%[14] - Cash and cash equivalents at the end of the period amount to CNY 221,236,734.65, down from CNY 578,525,332.22 at the end of the previous period[21] Operating Costs and Expenses - The company reported a 40.47% reduction in operating costs, amounting to ¥259,732,186.01, due to increased sales of high-margin products[8] - Total operating costs amounted to ¥510,263,351.88, down from ¥737,869,165.84, reflecting a reduction of approximately 31%[17] - Sales expenses decreased to CNY 152,633,062.39 from CNY 203,977,855.39, indicating improved cost management[18] - Financial expenses increased by 33.13% to ¥18,099,071.99, attributed to higher interest expenses[8] - The company experienced a decrease in financial expenses to CNY 18,099,071.99 from CNY 13,595,526.79, primarily due to lower interest expenses[18] Assets and Liabilities - Total assets decreased by 5.77% to ¥4,085,629,347.68 from ¥4,335,978,261.75 at the end of the previous year[4] - Total assets decreased to ¥4,085,629,347.68 from ¥4,335,978,261.75, a decline of about 6%[16] - Total liabilities decreased to ¥2,613,835,276.32 from ¥2,876,574,008.51, reflecting a reduction of approximately 9%[16] - The company's total equity increased to ¥1,471,794,071.36 from ¥1,459,404,253.24, showing a growth of about 1%[16] Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 30,352, with the largest shareholder holding 21.79% of the shares[9] Research and Development - The company has ongoing research and development efforts for new products, although specific details were not disclosed in the call[17] - Research and development expenses increased to CNY 17,179,625.28 from CNY 15,349,082.71, reflecting a focus on innovation[18] Future Outlook - Future outlook includes potential market expansion strategies, but no specific targets or timelines were provided[17] Impairment and Losses - The company experienced a 4433.56% increase in credit impairment losses, totaling ¥41,199,257.46, due to a decrease in accounts receivable[8] - The company reported a net loss of ¥84,630,131.32, an improvement compared to a net loss of ¥90,281,280.82 in the previous period[16] - Accounts receivable decreased to ¥416,191,421.95 from ¥569,106,113.41, representing a reduction of approximately 27%[14]